Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesSingle-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology
Journal of Clinical Oncology, 09/17/09
Brugières L et al. – Vinblastine is highly efficient in relapsed ALCL and may produce durable remissions
Methods- 36 pediatric patients with ALCL who were treated with vinblastine (6 mg/m2/wk) for resistant primary disease (1), a first relapse (15), or subsequent relapses (20)
- 15 patients had undergone hematopoietic stem-cell transplantation (HSCT) for a previous relapse
- 6patients were not evaluable for response, 25 (83%) of 30 evaluable patients achieved a CR, and 5 experienced PD
- Among the 31 patients who achieved a CR with vinblastine or before its initiation, 6 patients were treated with HSCT and 25 with vinblastine alone (median duration, 14 mos)
- Overall, 9 of 25 patients treated with vinblastine alone have remained in CR (median, 7 years since the end of treatment), and 16 patients have relapsed
- Vinblastine was still efficient for subsequent relapses
- With a median follow-up of 9.2 years, 12 patients have died (4 as a result of toxicity after HSCT and 8 as a result of disease), and 24 patients are alive (15 following treatment with single-agent vinblastine for the last event)
- 5-year overall survival is 65%, and 5-year event-free survival is 30%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
Journal of Clinical Oncology, 12/04/09
Immunoglobulin G Fc Receptor FcgammaRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma
Journal of Clinical Oncology, 12/04/09
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Infantile Fibrosarcoma: Management Based on the European Experience
Journal of Clinical Oncology, 12/04/09
Current Approach to Pediatric Soft Tissue Sarcomas
The Oncologist, 12/03/09
Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia
Hematology, 12/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma
BMC Cancer, 12/04/09
EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
European Journal of Cancer, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor